Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPP escalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients

Peter Borchmann, MD, Sven Trelle, Michaela Rancea, Heinz Haverkamp, Volker Diehl, MD, Nicole Skoetz, MD, Andreas Engert, MD

Blood (2012) 120 (21): 551.

https://doi.org/10.1182/blood.V120.21.551.551

Published: 2012

Journal Articles

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Julia Bohlius, MD, MScPH, Corinne Brillant, Michael Clarke, PhD, Sabine Kluge, Maryann Napoli, Margaret Piper, PhD, MPH, Dirk Rades, MD, PhD, Isabelle Ray-Coquard, MD, Kurt Schmidlin, MD, MPH, Martin Schumacher, PhD, Guido Schwarzer, PhD, Jerome Seidenfeld, MSc, PhD, David P. Steensma, MD, FACP, Sven Trelle, MD, Michael Untch, MD, Olaf Weingart, MD, Marcel Zwahlen, PhD, Matthias Egger, MD, MSc, Andreas Engert, MD

Blood (2008) 112 (11): lba-6.

https://doi.org/10.1182/blood.V112.11.lba-6.lba-6

Published: 2008

Journal Articles

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Julia Bohlius, MD, MScPH, Corinne Brillant, Michael Clarke, DPhil, Sabine Kluge, Maryann Napoli, Margaret Piper, PhD, MPH, Dirk Rades, MD, PhD, Martin Schumacher, PhD, Kurt Schmidlin, Guido Schwarzer, PhD, Jerome Seidenfeld, MSc, PhD, David P. Steensma, MD, FACP, Sven Trelle, Olaf Weingart, MD, Marcel Zwahlen, Matthias Egger, MD, MSc, Andreas Engert, MD

Blood (2008) 112 (11): 4675.

https://doi.org/10.1182/blood.V112.11.4675.4675

Published: 2008

Journal Articles

Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.

Holger Schulz, Julia Bohlius, Nicole Skoetz, Sven Trelle, Marcel Reiser, Thilo Kober, Guido Schwarzer, Michael Herold, Martin Dreyling, Andreas Engert

Blood (2006) 108 (11): 2760.

https://doi.org/10.1182/blood.V108.11.2760.2760

Published: 2006

Journal Articles

Bortezomib Is Not Active in Patients with Relapsed Hodgkin’s Lymphoma: Results of a Prematurely Closed Phase II Study.

Sven Trelle, Orhan Sezer, Ralph Naumann, Mathias Rummel, Ulrich Keller, Maike Nickelsen, Andreas Engert, Peter Borchmann

Blood (2006) 108 (11): 2477.

https://doi.org/10.1182/blood.V108.11.2477.2477

Published: 2006

Journal Articles

Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis.

Holger Schulz, MD, Nicole Skoetz, Julia Bohlius, MD, Sven Trelle, MD, Thilo Kober, Alexander Greb, Andreas Engert

Blood (2005) 106 (11): 351.

https://doi.org/10.1182/blood.V106.11.351.351

Published: 2005

Journal Articles

Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.

Julia Bohlius, MD, MScPH, Jayne Wilson, MSc, Sue Bayliss, MSc, Benjamin Djulbegovic, MD, PhD, Chris Hyde, MD, Msc, Sven Trelle, MD, Olaf Weingart, MD, Susan Brunskill, MSc, Josie Sandercock, MSc, Jerome Seidenfeld, MSc, PhD, Margaret Piper, MSc, PhD, Simon Langensiepen, MD, Guido Schwarzer, MSc, PhD, Charles Bennett, MD, PhD, Andreas Engert, MD

Blood (2005) 106 (11): 751.

https://doi.org/10.1182/blood.V106.11.751.751

Published: 2005

Journal Articles

Reporting of Randomised Controlled Trials in Hodgkin’s Lymphoma from 1966 to 2002. A Pre- and after CONSORT Evaluation.

Thilo Kober, MNA, Sven Trelle, MD, Alex Greb, MD, Nicole Skoetz, MD, Andreas Engert, MD

Blood (2005) 106 (11): 1336.

https://doi.org/10.1182/blood.V106.11.1336.1336

Published: 2005

Journal Articles

Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

Holger Schulz, MD, Sven Trelle, MD, Marcel Reiser, PhD, Marcus Sieber, MD, Volker Diehl, Andreas Engert

Blood (2005) 106 (11): 1503.

https://doi.org/10.1182/blood.V106.11.1503.1503

Published: 2005

NARROW

First Line Treatment of Advanced Stage Hodgkin Lymphoma with Six Cycles of BEACOPP escalated Results in Superior Overall Survival Compared to ABVD: Results of a Network Meta-Analysis Including 10,011 Patients

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Recombinant Human Erythropoiesis Stimulating Agents in Cancer Patients: Individual Patient Data Meta-Analysis on Behalf of the EPO IPD Meta-Analysis Collaborative Group

Combined Immunochemotherapy with Rituximab Improves Overall Survival in Patients with Follicular and Mantle Cell Lymphoma: Updated Meta-Analysis Results.

Bortezomib Is Not Active in Patients with Relapsed Hodgkin’s Lymphoma: Results of a Prematurely Closed Phase II Study.

Does Combined Immunochemotherapy with the Monoclonal Antibody Rituximab Improve Overall Survival in the Treatment of Patients with Indolent Non-Hodgkin Lymphoma? Preliminary Results of a Comprehensive Meta-Analysis.

Epoetin and Darbepoetin To Treat Cancer Patients: Updated Meta-Analysis Results.

Reporting of Randomised Controlled Trials in Hodgkin’s Lymphoma from 1966 to 2002. A Pre- and after CONSORT Evaluation.

Rituximab in Relapsed Lymphocyte Predominant Hodgkin’s Disease (LPHD). Long-Term Results of a Phase-II Study from the German Hodgkin Lymphoma Study Group (GHSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only